FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically to immunoglobulins binding a disintegrin and metalloproteinase with thrombospondin motifs 5 (hereinafter – ADAMTS5); it can be used in medicine for the treatment or prevention in an individual of a disease or a disorder, in which ADAMTS5 activity is involved. Polypeptide binding ADAMTS5 is proposed, containing at least 1 immunoglobulin single variable domain (ISVD) binding ADAMTS5 and containing 3 complementarity determining regions: CDR1 with SEQ ID NO: 21, CDR2 with SEQ ID NO: 37, and CDR3 with SEQ ID NO: 55.
EFFECT: invention provides polypeptides, which are ADAMTS5 antagonists relatively to inhibition of its enzyme activity with preservation of selectivity, showing improved preventive, therapeutic, and/or pharmacological properties, including a better safety profile compared to known antibodies to ADAMTS5.
26 cl, 14 dwg, 36 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDES BINDING TO ADAMTS5, MMP13, AND AGGRECAN | 2018 |
|
RU2786659C2 |
| MMP13-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2784069C2 |
| ADVANCED SERUM ALBUMIN BINDING AGENTS | 2018 |
|
RU2797270C2 |
| IMPROVED SUBSTANCES BINDING TO SERUM ALBUMIN | 2018 |
|
RU2789495C2 |
| IMPROVED TNF-BINDING AGENTS | 2016 |
|
RU2774823C2 |
| IMPROVED SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS BINDING TO SERUM ALBUMIN | 2017 |
|
RU2765384C2 |
| PD1/CTLA4-BINDING SUBSTANCES | 2016 |
|
RU2755724C2 |
| IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS | 2015 |
|
RU2809788C2 |
| IMPROVED VARIABLE DOMAINS OF IMMUNOGLOBULINS | 2015 |
|
RU2746738C2 |
| IMMUNOGLOBULINS BINDING AGGRECAN | 2018 |
|
RU2771818C2 |
